Log In
BCIQ
Print this Print this
 

CPI-444 (formerly V81444)

  Manage Alerts
Collapse Summary General Information
Company Vernalis plc
DescriptionOral small molecule adenosine A2A receptor (ADORA2A) antagonist
Molecular Target Adenosine A2A receptor (ADORA2A)
Mechanism of ActionAdenosine A2A receptor antagonist
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase I
Standard IndicationSolid tumors
Indication DetailsTreat solid tumors
Regulatory Designation
PartnerCorvus Pharmaceuticals Inc.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

2

$201.0M

$1.0M

$200.0M


 Deals Details
Get a free BioCentury trial today